Literature DB >> 10794727

Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

G H Goodfellow1, J M Dupret, D M Grant.   

Abstract

The human arylamine N-acetyltransferases NAT1 and NAT2 catalyse the acetyl-CoA-dependent N- and O-acetylation of primary arylamine and hydrazine xenobiotics and their N-hydroxylated metabolites. We previously used a panel of recombinant NAT1/NAT2 chimaeric proteins to identify linear amino acid segments that have roles in imparting the distinct catalytic specificities to these proteins [Dupret, Goodfellow, Janezic and Grant (1994) J. Biol. Chem. 269, 26830-26835]. These studies indicated that a conserved central region (residues 112-210) distinct from that containing the active-site cysteine residue Cys(68) was important in determining NAT substrate selectivity. In the present study we have refined our analysis through further chimaera generation of this conserved region and by subsequent site-directed mutagenesis of individual amino acids. Enzyme-kinetic analysis of these mutant proteins with the NAT1-selective and NAT2-selective substrates p-aminosalicylic acid (PAS) and sulphamethazine (SMZ) respectively suggests that residues 125, 127 and 129 are important determinants of NAT1-type and NAT2-type substrate selectivity. Modification of Arg(127) had the greatest effect on specificity for PAS, whereas changing Phe(125) had the greatest effect on specificity for SMZ. Selected NAT mutants exhibited K(m) values for acetyl-CoA that were comparable with those of the wild-type NATs, implying that the mutations affected acceptor substrate specificity rather than cofactor binding affinity. Taken together with previous observations, these results suggest that residues 125, 127 and 129 might contribute to the formation of the active-site pocket surrounding Cys(68) and function as important determinants of NAT substrate selectivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794727      PMCID: PMC1221049     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Evolution of a protein fold in vitro.

Authors:  M H Cordes; N P Walsh; C J McKnight; R T Sauer
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

Authors:  D M Grant; K Mörike; M Eichelbaum; U A Meyer
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

4.  Use of polymerase chain reaction catalyzed by Taq DNA polymerase for site-specific mutagenesis.

Authors:  H Kadowaki; T Kadowaki; F E Wondisford; S I Taylor
Journal:  Gene       Date:  1989-03-15       Impact factor: 3.688

5.  Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver.

Authors:  D M Grant; F Lottspeich; U A Meyer
Journal:  FEBS Lett       Date:  1989-02-13       Impact factor: 4.124

6.  Construction of mutant and chimeric genes using the polymerase chain reaction.

Authors:  F Vallette; E Mege; A Reiss; M Adesnik
Journal:  Nucleic Acids Res       Date:  1989-01-25       Impact factor: 16.971

7.  Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2.

Authors:  J M Dupret; D M Grant
Journal:  J Biol Chem       Date:  1992-04-15       Impact factor: 5.157

8.  Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms.

Authors:  M Watanabe; T Sofuni; T Nohmi
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

9.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

Authors:  M Blum; D M Grant; W McBride; M Heim; U A Meyer
Journal:  DNA Cell Biol       Date:  1990-04       Impact factor: 3.311

10.  Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.

Authors:  D M Grant; M Blum; M Beer; U A Meyer
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

View more
  23 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

Authors:  F Rodrigues-Lima; C Deloménie; G H Goodfellow; D M Grant; J M Dupret
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

3.  Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1.

Authors:  Haiqing Wang; Gregory M Vath; Akane Kawamura; Caleb A Bates; Edith Sim; Patrick E Hanna; Carston R Wagner
Journal:  Protein J       Date:  2005-02       Impact factor: 2.371

4.  Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese.

Authors:  Lan Hong; Wendy Jiang; Hao Pan; Yueming Jiang; Su Zeng; Wei Zheng
Journal:  Drug Metab Dispos       Date:  2011-07-18       Impact factor: 3.922

5.  Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2.

Authors:  Jason M Walraven; Mark A Doll; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2006-07-07       Impact factor: 4.030

Review 6.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 7.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

8.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.

Authors:  Jason M Walraven; John O Trent; David W Hein
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.